Matching articles for "loteprednol"
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • March 31, 2025; (Issue 1725)
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table...
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).
Drugs for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • March 3, 2025; (Issue 1723)
Disruption of tear-film homeostasis (altered
composition, reduced production, rapid evaporation)
and resulting ocular surface inflammation cause the
discomfort and blurred vision of dry eye disease.
Many...
Disruption of tear-film homeostasis (altered
composition, reduced production, rapid evaporation)
and resulting ocular surface inflammation cause the
discomfort and blurred vision of dry eye disease.
Many cases are caused by tear evaporation due to
meibomian gland dysfunction. Other precipitating
factors can include lacrimal gland dysfunction, poor
eyelid function, environmental factors, extended
screen time, inflammatory conditions such as
Sjögren's syndrome, and use of some ocular or
systemic drugs such as antihistamines, retinoids,
or selective serotonin reuptake inhibitors (SSRIs).
Benzalkonium chloride, a preservative used in some
eye drops, can cause eye irritation and exacerbate
symptoms of dry eye disease; use of preservative-free
ophthalmic preparations is preferred. Dry eye disease
is most prevalent in females and older adults, but its incidence in young people is increasing, possibly
because of increased screen time.
Perfluorohexyloctane Ophthalmic Solution (Miebo) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • January 22, 2024; (Issue 1694)
The FDA has approved perfluorohexyloctane
ophthalmic solution (Miebo – Bausch+Lomb) for
treatment of dry eye disease. Available only by
prescription, Miebo is the first ophthalmic product to be approved in...
The FDA has approved perfluorohexyloctane
ophthalmic solution (Miebo – Bausch+Lomb) for
treatment of dry eye disease. Available only by
prescription, Miebo is the first ophthalmic product to be approved in the US that specifically targets tear
evaporation caused by meibomian gland dysfunction.
An ophthalmic solution with a similar name, Meibo
Tears (Vista), which contains 0.6% propylene glycol, is
available over the counter for dry eye relief.
Cyclosporine Ophthalmic Emulsion (Verkazia) for Vernal Keratoconjunctivitis
The Medical Letter on Drugs and Therapeutics • May 1, 2023; (Issue 1675)
The FDA has approved Verkazia (Santen), a 0.1%
ophthalmic emulsion formulation of the calcineurin
inhibitor cyclosporine, for treatment of vernal
keratoconjunctivitis (VKC). Verkazia is the first
product to...
The FDA has approved Verkazia (Santen), a 0.1%
ophthalmic emulsion formulation of the calcineurin
inhibitor cyclosporine, for treatment of vernal
keratoconjunctivitis (VKC). Verkazia is the first
product to be approved in the US for this indication.
A Dexamethasone Ophthalmic Insert (Dextenza) for Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • March 20, 2023; (Issue 1672)
The FDA has approved Dextenza (Ocular Therapeutix),
a dexamethasone ophthalmic insert, for
treatment of ocular itching associated with allergic
conjunctivitis. Dextenza was approved earlier for
treatment of...
The FDA has approved Dextenza (Ocular Therapeutix),
a dexamethasone ophthalmic insert, for
treatment of ocular itching associated with allergic
conjunctivitis. Dextenza was approved earlier for
treatment of ocular inflammation and pain following
ophthalmic surgery.
A Drug-Eluting Contact Lens for Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • April 18, 2022; (Issue 1648)
The FDA has approved Acuvue Theravision with
Ketotifen (Johnson & Johnson Vision Care), a daily-wear,
disposable, vision-correcting soft contact
lens that releases the H1-antihistamine ketotifen,...
The FDA has approved Acuvue Theravision with
Ketotifen (Johnson & Johnson Vision Care), a daily-wear,
disposable, vision-correcting soft contact
lens that releases the H1-antihistamine ketotifen, for
prevention of ocular itch due to allergic conjunctivitis
in contact lens users. This is the first approval for a
drug-eluting contact lens. Ketotifen eye drops (Alaway,
Zaditor, and others) are available over the counter.
Varenicline Nasal Spray (Tyrvaya) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • December 13, 2021; (Issue 1639)
Tyrvaya (Oyster Point), a nasal spray formulation
of the cholinergic agonist varenicline, has been
approved by the FDA for treatment of dry eye disease.
It is the first nasal spray to be approved in the...
Tyrvaya (Oyster Point), a nasal spray formulation
of the cholinergic agonist varenicline, has been
approved by the FDA for treatment of dry eye disease.
It is the first nasal spray to be approved in the US
for this indication. An oral formulation of varenicline
(Chantix, and generics) has been available for years
for smoking cessation.
Loteprednol 0.25% (Eysuvis) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • May 17, 2021; (Issue 1624)
The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis – Kala) for
short-term treatment (≤2 weeks) of dry eye disease.
It is the first ocular corticosteroid to be approved...
The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis – Kala) for
short-term treatment (≤2 weeks) of dry eye disease.
It is the first ocular corticosteroid to be approved for
this indication. Other formulations of loteprednol are
approved for treatment of steroid-responsive ocular
inflammatory conditions, inflammation after ocular
surgery, and seasonal allergic conjunctivitis.
Drugs for Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • April 19, 2021; (Issue 1622)
The choice of drugs for treatment of allergic rhinitis
depends on the severity of symptoms and whether
they are intermittent or persistent (see Table...
The choice of drugs for treatment of allergic rhinitis
depends on the severity of symptoms and whether
they are intermittent or persistent (see Table 1).
OTC Drugs for Seasonal Allergies
The Medical Letter on Drugs and Therapeutics • April 22, 2019; (Issue 1570)
Patients with seasonal allergies often experience
nasal itching and congestion, sneezing, rhinorrhea,
and itchy, watery eyes. Oral, intranasal, and ophthalmic
preparations are widely available over the...
Patients with seasonal allergies often experience
nasal itching and congestion, sneezing, rhinorrhea,
and itchy, watery eyes. Oral, intranasal, and ophthalmic
preparations are widely available over the counter
(OTC) for relief of symptoms. Prescription products for
management of allergic rhinitis and allergic conjunctivitis
are reviewed separately.
Drugs for Allergic Disorders
The Medical Letter on Drugs and Therapeutics • May 8, 2017; (Issue 1520)
Allergic rhinitis can be classified as seasonal,
perennial, or episodic. It is often associated with
allergic conjunctivitis, rhinosinusitis, and asthma. H1-ANTIHISTAMINES — Oral – Oral...
Allergic rhinitis can be classified as seasonal,
perennial, or episodic. It is often associated with
allergic conjunctivitis, rhinosinusitis, and asthma.
H1-ANTIHISTAMINES — Oral – Oral second-generation H1-antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
H1-ANTIHISTAMINES — Oral – Oral second-generation H1-antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.